Clinical trial · Observational
Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients
Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients: Impact on Immunity Versus Immunosuppression
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Melanoma tumor tissue ( in particular regressive areas) present a lymphocytic infiltrate with an anti-tumoral specificity. The aim of the study is to analyse at different stages of the disease, tumor samples and to characterise the cellular infiltrate in situ ( in particular T lymphocytes, NK cells and macrophages), the role of inhibitor receptors on in situ immunosuppression, and potential modulation by medical treatments such as dacarbazine.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biological collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- MELANOMA 10mm
- description
- patients with a melanoma larger than 10mm or with cutaneous metastasis
- interventionNames
- Other: biological collection
- label
- STAGE III MELANOMA
- description
- stage III melanoma patients who shall undergo a regional lymph node dissection
- interventionNames
- Other: biological collection
- label
- SENTINEL NODE PROCEDURE
- description
- retrospective study of patients who underwent a sentinel node procedure
- interventionNames
- Other: biological collection
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with confirmed melanoma-patients informed of the aims of the study , the modalities * Patients who signed the consent form ou a non opposition form signed by the patient or by a relative According to study part: Part 1: patients with a melanoma larger than 10mm or with cutaneous metastasis Part 2: stage IV melanoma patients who shall undergo a regional lymph node dissection Part 3: retrospective study of patients who underwent a sentinel node procedure Part 4: Patients achieves of inoperable melanomas the stage(stadium) III or IV that must receive in treatment (processing) a chemotherapy (by the dacarbazine or by the cisplatin or by the inhibitor of B-raf) and carrier of at least two cutaneous metastases Exclusion Criteria: * Refusal to take part in the study (patient or relative) * Contraindications known to the xylocaine (groups 1,2, and 4) * No affiliated to the social security system (groups 1, 2, and 4)
References
Publications (1)
- RESULTMessaoudene M, Perier A, Fregni G, Neves E, Zitvogel L, Cremer I, Chanal J, Sastre-Garau X, Deschamps L, Marinho E, Larousserie F, Maubec E, Avril MF, Caignard A. Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients. PLoS One. 2015 Jul 28;10(7):e0133363. doi: 10.1371/journal.pone.0133363. eCollection 2015. PMID 26218530